bioRxivCancer BiologyPreprint
Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma
M. F. Gonzalez-Aponte, A. R. Damato, L. L. Trebucq, T. Simon, S. P. Cardenas-Garcia, K. Cho, G. J. Patti, D. A. Golombek, J. J. Chiesa, E. D. Herzog
Abstract
BackgroundGlioblastoma (GBM) is the most common primary brain tumor in adults. Despite extensive research and clinical trials, median survival post-treatment remains at 15 months. Thus, all opportunities to optimize current treatments and improve patient outcomes should be considered. A recent retrospective clinical study found that taking TMZ in the morning compared to the evening was associated with a 6-month increase in median survival in patients with MGMT-methylated GBM. Here, we hypothesized that TMZ efficacy depends on time-of-day and O6-Methylguanine-DNA Methyltransferase (MGMT) activity in murine and human models of GBM. Methods and ResultsIn vitro recordings using real-time bioluminescence reporters revealed that GBM cells have intrinsic circadian rhythms in the expression of the core circadian clock genes Bmal1 and Per2, as well as in the DNA repair enzyme, MGMT. Independent measures of MGMT transcript levels and promoter methylation also showed daily rhythms intrinsic to GBM cells. These cells were more susceptible to TMZ when delivered at the daily peak of Bmal1 transcription. We found that in vivo morning administration of TMZ also decreased tumor size and increased body weight compared to evening drug delivery in mice bearing GBM xenografts. Finally, inhibition of MGMT activity with O6-Benzylguanine abrogated the daily rhythm in sensitivity to TMZ in vitro by increasing sensitivity at both the peak and trough of Bmal1 expression. ConclusionWe conclude that chemotherapy with TMZ can be dramatically enhanced by delivering at the daily maximum of tumor Bmal1 expression and minimum of MGMT activity. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=164 SRC="FIGDIR/small/557630v1_ufig1.gif" ALT="Figure 1"> View larger version (36K): org.highwire.dtl.DTLVardef@2e9058org.highwire.dtl.DTLVardef@1069917org.highwire.dtl.DTLVardef@2cf000org.highwire.dtl.DTLVardef@40abc9_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- organism: human
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Glioblastoma recurrence and the role of MGMT promoter methylation
Katie Storey, Kevin Leder, … Jasmine Foo·bioRxiv·May 9, 2018
- Daily glucocorticoids promote glioblastoma growth and circadian synchrony to the host
Maria F. Gonzalez-Aponte, Anna R. Damato, … Erik D. Herzog·Cancer CellPeer-reviewed·Dec 12, 2024
- Temporal control of tumor growth in nocturnal mammals: impact of the circadian system
P. M. Wagner, C. Prucca, … M. E. GUIDO·bioRxiv·May 25, 2020
- Pharmacological modulation of the cytosolic oscillator affects glioblastoma cell biology
P. M. Wagner, M. E. Guido·bioRxiv·Nov 23, 2023
- Multicellular model of temozolomide resistance in glioblastoma reveals phenotypic shifts in drug response and migratory potential
Victoria A. Kriuchkovskaia, Ela K. Eames, … Brendan A.C. Harley·bioRxiv·Jul 8, 2025
- Sensitivity to temozolomide of cell lines derived from brain tumours and melanomas: relationship to MGMT gene expression
Bruce C. Baguley, Wayne R. Joseph, … Elaine S Marshall·bioRxiv·Nov 30, 2024